Amed Co (7575) Fair Value & Analysis
Healthcare · TW · Market cap 573M TWD
Fair value as of: Jun 24, 2026
Analysis
Amed Co (7575) currently trades at 18.75 TWD, while our model-based Fair Value estimate is 21.34 TWD — implying the stock looks roughly 13.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Amed Co., Ltd. engages in the research and development, manufacture, and trading of medical equipment in Taiwan. It offers wound care dressing products under the HERADERM brand name; negative pressure wound therapy systems that provides 24-hour oxygen supply to wounds under the Genadyne brand name; and wound treatment systems under the Natrox brand name. The company also provides 7-day long-acting pain reliever injections under the Naldebain brand name. In addition, it offers pressure injectable implantable port kits under the POLYSITE brand; and universal linear cutting staplers under the easyEndo brand name. The company was founded in 2008 and is based in New Taipei City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Amed Co (7575) undervalued?
What is the fair value of 7575?
What is the quality score of 7575?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.